Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
3
75%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)

Detailed Status

Recruiting2
Withdrawn1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

withdrawn125%
recruiting250%
completed125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_1

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

NCT05661201
recruitingphase_1

Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

NCT04365179
withdrawnphase_2

A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

NCT03059615
completedphase_1

Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies

NCT01690741

Clinical Trials (4)

Showing 4 of 4 trials
NCT05661201Phase 1

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Recruiting
NCT04365179Phase 1

Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

Recruiting
NCT03059615Phase 2

A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

Withdrawn
NCT01690741Phase 1

Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4